We recently compiled the list of 25 Best Dividend Aristocrats Stocks According to Analysts. Since AbbVie Inc. (NYSE:ABBV) is part of our list, we have analyzed the stock in detail. The age-old debate of investing in dividend growth or high-yield stocks continues to reappear within the dividend investing realm. Between these two, dividend growth is currently […]
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE®) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9% (95%CI 40.4 – 63.3%).